Blue Trust Inc. Buys 21,958 Shares of Elanco Animal Health Incorporated $ELAN

Blue Trust Inc. raised its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1,436.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,487 shares of the company’s stock after acquiring an additional 21,958 shares during the quarter. Blue Trust Inc.’s holdings in Elanco Animal Health were worth $562,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. NewEdge Advisors LLC lifted its stake in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the period. Root Financial Partners LLC grew its stake in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. purchased a new stake in Elanco Animal Health in the fourth quarter worth $41,000. Huntington National Bank raised its holdings in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares in the last quarter. Finally, Torren Management LLC bought a new position in Elanco Animal Health in the fourth quarter worth $46,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ELAN shares. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Citigroup lifted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. TD Cowen increased their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.55.

Elanco Animal Health Price Performance

NYSE ELAN opened at $24.56 on Friday. Elanco Animal Health Incorporated has a one year low of $13.39 and a one year high of $27.72. The stock has a 50-day moving average of $23.04 and a 200 day moving average of $23.56. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a market capitalization of $12.27 billion, a price-to-earnings ratio of -49.12, a PEG ratio of 1.61 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the prior year, the business earned $0.37 EPS. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.